Arvinas, Inc. reported a net loss of $80.8 million for the year ended December 31, 2025, a significant decrease from the $198.9 million and $367.3 million losses reported for 2024 and 2023, respectively. The company's revenue remained relatively stable at $262.6 million in 2025 compared to $263.4 million in 2024. Research and development expenses decreased to $285.2 million in 2025 from $348.2 million in 2024, while general and administrative expenses also saw a substantial reduction, falling to $95.9 million from $165.4 million. The company attributed the revenue stability to offsetting factors, including decreased revenue from the Novartis licensing agreement and the Pfizer Research Collaboration Agreement, balanced by increased revenue from the Vepdegestrant collaboration with Pfizer and a $20.0 million development milestone payment from Novartis.
The decrease in research and development expenses was primarily due to lower compensation-related costs and reduced external expenses across several programs. General and administrative expenses decreased due to a loss on the termination of a lease in 2024, lower personnel and infrastructure costs, and reduced professional fees. Other income decreased to $38.0 million in 2025 from $51.9 million in 2024, mainly due to lower interest income from marketable securities. The company's income tax expense was $0.3 million in 2025, compared to $0.6 million in 2024.
Operationally, Arvinas made significant strides in its clinical programs. The FDA accepted the New Drug Application (NDA) for vepdegestrant, with a PDUFA date of June 5, 2026. The company also completed dose escalation for ARV-806 and initiated a Phase 1 clinical trial for ARV-027. Preclinical data for ARV-6723 and a pan-KRAS degrader were presented at major conferences, supporting their potential as cancer therapies. The company also announced that it and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.
Arvinas implemented cost-saving measures, including workforce reductions of approximately 33% in April 2025 and an additional 15% in September 2025, aimed at streamlining operations and reducing costs. These actions are expected to yield annual operating cost savings of $100.0 million on a run-rate basis. As of December 31, 2025, Arvinas had cash, cash equivalents, and marketable securities totaling $685.4 million, which the company believes will be sufficient to fund operations into the second half of 2028. The company's strategic focus remains on advancing its oncology and neurology pipeline, expanding its PROTAC Discovery Engine, and selectively collaborating to maximize the value of its assets.
About ARVINAS, INC.
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies using its proprietary PROTAC technology to degrade disease-causing proteins. Targeting oncology and neurodegenerative diseases, its key products include vepdegestrant for breast cancer and ARV-102 for Parkinson's disease. With a robust pipeline addressing historically undruggable targets, Arvinas aims to transform treatment paradigms and improve patient outcomes through strategic collaborations and advanced drug development initiatives.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.